Insider buying · SEC Form 4

Insider Buying — Jul 24, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

1insider buy
$2.58Mbought in total
1company
0by CEOs, CFOs and other chiefs
ARTVlargest: $2.58M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
ARTVArtiva Biotherapeutics, Inc.RA Capital Management, L.P. / Peter KolchinskyDirector / 10% Owner$2.58M264,586$9.76AddedJul 23, 2026
Form 4 ↗
3-day cluster buy: 120,582 shares @ $9.55 avg (Jul 21, range $9.16–$10.00), 84,124 @ $9.93 avg (Jul 22, range $9.72–$10.00), 59,880 @ $9.96 avg (Jul 23, range $9.40–$10.00). Weighted avg buy price ~$9.76; current spot $10.13 (+3.8%). RA Capital adds to existing ~17.2M-share position; co-filers include Rajeev Shah (Director). Consistent accumulation capped at $10 round-number level across all three sessions.

AIThe day in insider buying

SEC Form 4 Insider Scan — July 24, 2026

Scanned the last 24 hours of EDGAR Form 4 filings. 1 qualifying buy (≥ $250K, transaction type P) totalling $2.58M.

Headline filings

  • ARTV — RA Capital Management / Peter Kolchinsky (Director & 10% Owner) bought 264,586 shares ≈ $2.58M across three consecutive sessions (Jul 21–23) at a weighted avg of $9.76; now $10.13 (+3.8% since buy). (filing)

Notes

Artiva Biotherapeutics (ARTV) was the only meaningful open-market buyer in today's scan. RA Capital Management (via RA Capital Healthcare Fund LP, RA Capital Nexus Fund III LP, and related entities) accumulated 264,586 shares over three consecutive sessions at prices ranging from $9.16 to $10.00 — capped near the round-number $10.00 level across all three days, suggesting deliberate accumulation below that mark. This is an addition to an already substantial ~17.2M-share position; RA Capital's principals Peter Kolchinsky and Rajeev Shah sit on the ARTV board, making this an informed-principal cluster buy in a small-cap biotech.

Outside ARTV, the day's Form 4 activity was dominated by routine compensation events: RSU grants/vests (United Therapeutics, InterDigital, BuzzFeed, Priority Technology Holdings), merger-conversion disposals (KORE Group Holdings acquisition at $9.25/share), rule 10b5-1 plan sales (Sea Ltd COO/GC, Viant Technology, CoreWeave CEO, StoneX Group executives), stock option exercises (StoneX CFO and GC, Cadence Design), and new-director option grants (United Therapeutics, Outlook Therapeutics). No other open-market purchases ≥ $250K were identified in the July 23–24 filing window.

Most-bought stocks, last 30 days

  • AVO $65.6M · 11 buys, 3 insidersMission Produce, Inc.
  • PBLS $16.9M · 2 buys, 2 insidersParabilis Medicines, Inc.
  • COE $12.1M · 3 buysChina Online Education Group
  • PSEC $9.35M · 3 buys, 2 insidersProspect Capital Corp
  • NTSK $7.53M · 2 buys, 2 insidersNetskope Inc.
  • HDSN $6.49M · 3 buys, 2 insidersHudson Technologies, Inc.
  • NVCT $4.66M · 8 buys, 2 insidersNuvectis Pharma, Inc.
  • ENR $3.71M · 3 buys, 2 insidersEnergizer Holdings, Inc.
  • GLOO $3.50M · 1 buyGloo Holdings, Inc.
  • ARTV $2.58M · 1 buyArtiva Biotherapeutics, Inc.
  • WBX $2.25M · 2 buys, 2 insidersWallbox N.V.
  • CLBK $2.13M · 5 buys, 5 insidersColumbia Financial, Inc.
  • GGAL $2.09M · 1 buyGrupo Financiero Galicia S.A.
  • NXST $1.99M · 1 buyNexstar Media Group, Inc.
  • ADBE $1.95M · 1 buyAdobe Inc
  • RH $1.83M · 1 buyRH
  • JCTC $1.61M · 2 buys, 2 insidersJewett-Cameron Trading Co. Ltd.
  • FULC $1.48M · 2 buys, 2 insidersFulcrum Therapeutics, Inc.
  • AMS $1.34M · 1 buyAmerican Shared Hospital Services
  • BOLD $1.25M · 3 buys, 2 insidersBoundless Bio, Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.